Caitong International Asset Management’s Anika Therapeutics ANIK Stock Holding History

Caitong International Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73	Buy	+5	New	+$74	﹤0.01%	2262

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Caitong International Asset Management's ANIK Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Anika Therapeutics (ANIK) in Q2 2026: 5 shares worth $73. The stake represents ﹤0.01% of the portfolio and ranks #2262 among its holdings.

133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

Caitong International Asset Management held 5 shares of Anika Therapeutics worth $73 as of Q2 2026.
Anika Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Anika Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2262 holding.
133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.